Getinge Group Year-End Report 2014

Reporting period January – December

• Order intake rose by 5.6% to SEK 26,817 M (25,395), and grew organically
  by 0.7%
• Net sales increased by 5.5% to SEK 26,669 M (25,287), and grew organically
  by 0.6%
• Profit before tax declined by 37.0% to SEK 1,987 M (3,153)
• Net profit fell by 36.9% to SEK 1,448 M (2,295)
• Earnings per share declined by 37.3% to SEK 6,01 (9,59)
• EBITA before restructuring decreased by 5.6% to SEK 4,501 M (4,766)
• Cash conversion from operating activities amounted to 72.9% (63.1%)
• A dividend per share of SEK 2.80 (4.15) is proposed, corresponding to SEK 667 M (989)
  
  

Reporting period October - December

• Order intake rose by 11.8% to SEK 7,747 M (6,931), and grew 3.0% organically
• Net sales increased by 9.0% to SEK 8,458 M (7,757), and grew 1.1% organically
• Profit before tax declined by 19.8% to SEK 1,371 M (1,709)
• EBITA before restructuring declined by 3.2% to SEK 1,994 M (2,060)
• Estimated financial consequences as a result of the discussions with the FDA are expected to have a negative impact of approximately SEK 500 M on operating profit, the entire amount of which will probably impact earnings for 2015. An additional SEK 175 M was recognized during the quarter for completing the remediation program, in addition to the SEK 820 M that was previously announced.

• Alex Myers appointed new President and CEO of Getinge Group
• Joacim Lindoff appointed new Executive Vice President of the Infection Control Business Area